Medpace (MEDP)
(Delayed Data from NSDQ)
$352.92 USD
-3.48 (-0.98%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $312.00 -40.92 (-11.59%) 5:02 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$352.92 USD
-3.48 (-0.98%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $312.00 -40.92 (-11.59%) 5:02 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Zacks News
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Select Medical (SEM) Up 18% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners
by Zacks Equity Research
Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.
Zacks.com featured highlights include Medpace, Invitation Home and Ryanair
by Zacks Equity Research
Medpace, Invitation Home and Ryanair are part of the Zacks Screen of the Week article.
3 Medical Services Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.
3 Top Stocks Exhibiting Superb Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as Medpace Holdings (MEDP), Invitation Home (INVH) and Ryanair Holdings (RYAAY) for solid earnings growth.
Acadia Healthcare (ACHC) Up 11% in 3 Months: More Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on an expansive healthcare portfolio, which in turn, boosts its patient volumes.
3 Reasons Growth Investors Will Love Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Medpace (MEDP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Medpace (MEDP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Medpace (MEDP) have performed compared to their sector so far this year.
Medpace (MEDP) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 1.58% and 6.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Soars 21.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Apollo Medical
by Zacks Equity Research
Medpace, HealthEquity and Apollo Medical are part of the Zacks Industry Outlook article.
Brookdale (BKD) May 2023 Occupancy Rises: Better Days Ahead?
by Zacks Equity Research
Brookdale (BKD) has witnessed 19 straight months of year-over-year increases in weighted average occupancy level.
3 Medical Services Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and AMEH are set to gain the most. However, staffing shortages may disrupt the trend.
Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities
by Zacks Equity Research
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
Should You Retain Acadia Healthcare (ACHC) in Your Portfolio?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is likely to receive support from growth in specialty treatment and acute inpatient psychiatric facilities.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.
Here's Why You Should Hold Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Improving top line, investments in high-growth businesses, membership hikes and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
Here is Why Growth Investors Should Buy Medpace (MEDP) Now
by Zacks Equity Research
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
New Strong Buy Stocks for May 3rd
by Zacks Equity Research
COCO, RYI, GTX, MEDP and SKX have been added to the Zacks Rank #1 (Strong Buy) List on May 3rd, 2023.